A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HRGN SEC filings page.
HARVARD APPRATS REG TCH (HRGN) reported $982K in revenue over the twelve months to Jun 30, 2026, up 44.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business is still funding a development-stage cost base, while higher sales have not yet produced durable gross economics or self-financing cash flow.
Revenue increased583.5% from FY2023 to FY2025, but gross margin fell68.5 pp , showing that added sales have not yet improved the economics of each sale. In FY2025, operating cash flow was-$3.83M against a net loss of$6.87M ; the gap suggests reported losses include substantial non-cash or working-capital effects rather than matching cash costs.
FY2025 research and development and selling, general and administrative costs equaled
FY2025 liabilities were
Financial Health Signals
HARVARD APPRATS REG TCH does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
HARVARD APPRATS REG TCH scores -49.06, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $106.6M against total assets of $2.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
HARVARD APPRATS REG TCH passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.
HARVARD APPRATS REG TCH reported a net loss of $6.9M while operations used $3.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
HARVARD APPRATS REG TCH reported an operating loss of $6.9M against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
HARVARD APPRATS REG TCH generated $414K in revenue in Q2 2026. This represents an increase of 30.6% from the same quarter a year earlier. Against the prior quarter it is up 83.2%.
HARVARD APPRATS REG TCH's EBITDA was -$1.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
HARVARD APPRATS REG TCH reported a net loss of $1.7M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
HARVARD APPRATS REG TCH held $351K in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
HARVARD APPRATS REG TCH's gross margin was 5.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
HARVARD APPRATS REG TCH invested $948K in research and development in Q2 2026. This represents an increase of 36.0% from the same quarter a year earlier. Against the prior quarter it is up 68.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
HRGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $414K+30.6% | $226K+402.2% | $219K-15.1% | $123K+108.5% | $317K+466.1% | $45K-21.1% | $258K | $59K+47.5% |
| Cost of Revenue | $391K+29.5% | $206K+524.2% | $199K+13.7% | $112K+60.0% | $302K+2223.1% | $33K+175.0% | $175K | $70K |
| Gross Profit | $23K+53.3% | $20K+66.7% | $20K-75.9% | $11Kn/m | $15K-65.1% | $12K-73.3% | $83K | -$11K |
| R&D Expenses | $948K+36.0% | $563K-6.3% | $700K+158.3% | $655K+17.6% | $697K+8.6% | $601K-28.5% | $271K | $557K+64.3% |
| SG&A Expenses | $751K-34.8% | $1.0M-3.3% | $976K-17.1% | $1.0M-19.1% | $1.2M-38.8% | $1.1M-11.8% | $1.2M | $1.3M-1.6% |
| Operating Income | -$1.7Mn/m | -$1.6Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.8Mn/m | -$1.7Mn/m | -$1.4M | -$1.9Mn/m |
| EBITDA | -$1.7Mn/m | -$1.6Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.8Mn/m | -$1.7Mn/m | -$1.4M | -$1.9Mn/m |
| Interest Expense | $8K+166.7% | $2K0.0% | $1K0.0% | $2K-81.8% | $3K-82.4% | $2K-77.8% | $1K | $11K |
| Income Tax | N/A | $0n/m | N/A | N/A | N/A | $0 | N/A | N/A |
| Net Income | -$1.7Mn/m | -$1.6Mn/m | -$1.7Mn/m | -$1.7Mn/m | -$1.8Mn/m | -$1.7Mn/m | -$1.3M | -$1.9Mn/m |
| EPS (Basic) | -$0.10n/m | -$0.09n/m | -$0.10n/m | -$0.10n/m | -$0.11n/m | -$0.10n/m | -$0.08n/m | -$0.12n/m |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.12n/m |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 15M+8.2% |
HRGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.7M-21.2% | $1.8M-47.3% | $2.7M-39.7% | $2.5M-52.1% | $2.1M-51.9% | $3.4M-23.1% | $4.4M+69.9% | $5.3M+40.4% |
| Current Assets | $789K-29.4% | $873K-62.1% | $1.8M-43.4% | $1.6M-59.1% | $1.1M+70.3% | $2.3M+273.1% | $3.2M+313.0% | $4.0M+110.3% |
| Cash & Equivalents | $351K-55.3% | $419K-75.8% | $1.4M-45.6% | $1.3M-63.3% | $786K+465.5% | $1.7M+535.3% | $2.5M+475.5% | $3.6M+1235.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% |
| Inventory | $0-100.0% | $15K-68.8% | $16K-80.0% | $22K-80.5% | $27K-55.0% | $48K+9.1% | $80K+60.0% | $113K+101.8% |
| Accounts Receivable | $9K+80.0% | $16K+300.0% | $16K-93.1% | $3K+200.0% | $5K | $4K-42.9% | $231K+5675.0% | $1K-66.7% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.1M+122.7% | $1.7M+24.8% | $1.6M+32.8% | $992K-32.6% | $1.4M-70.9% | $1.4M-68.0% | $1.2M+26.0% | $1.5M+38.0% |
| Current Liabilities | $3.0M+147.1% | $1.7M+38.2% | $1.5M+50.2% | $876K-29.8% | $1.2M-38.2% | $1.2M-46.7% | $1.0M+5.5% | $1.2M+18.2% |
| Non-Current Liabilities | $22K-84.8% | $55K-68.0% | $86K-56.8% | $116K-48.2% | $145K-94.7% | $172K-91.5% | $199Kn/m | $224K+1936.4% |
| Total Equity | -$1.4M-281.2% | $92K-95.5% | $1.1M-67.2% | $1.6M-59.5% | $761Kn/m | $2.0M+1070.3% | $3.2M+95.7% | $3.8M+41.4% |
| Retained Earnings | -$109.9Mn/m | -$108.2Mn/m | -$106.6Mn/m | -$104.9Mn/m | -$103.2Mn/m | -$101.3Mn/m | -$99.7Mn/m | -$98.3Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
HRGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$569Kn/m | -$937Kn/m | -$664Kn/m | -$1.5Mn/m | -$941Kn/m | -$758Kn/m | -$1.1Mn/m | -$1.5Mn/m |
| Depreciation & Amortization | $1K0.0% | $1K-50.0% | $1K-50.0% | $1K0.0% | $1K-80.0% | $2K-66.7% | $2K-66.7% | $1K-83.3% |
| Stock-Based Compensation | $200K-60.0% | $632K+30.3% | N/A | N/A | $500K-12.6% | $485K-13.4% | N/A | $562K+5.0% |
| Financing Cash Flow | N/A | N/A | $700Kn/m | $2.0M-59.4% | $0-100.0% | $0-100.0% | $0-100.0% | $4.9Mn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
HRGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.6%+0.8pp | 8.8%-17.8pp | 9.1%-23.0pp | 8.9%+27.6pp | 4.7%-72.1pp | 26.7%-52.3pp | 32.2% | -18.6% |
| Operating Margin | -408.7% | -710.6% | -775.3% | -1393.5% | -578.2% | -3711.1% | -529.1% | -3150.8% |
| Net Margin | -409.4% | -708.4% | -770.3% | -1382.1% | -575.1% | -3686.7% | -520.9% | -3152.5% |
| Return on Equity | N/A | -1740.2%-1659.2pp | -159.6%-117.9pp | -109.4%-61.0pp | -239.6% | -81.0%+1079.0pp | -41.7% | -48.4%+11.0pp |
| Return on Assets | -100.6%-15.3pp | -89.0%-40.5pp | -63.0%-32.8pp | -66.8%-31.7pp | -85.3%-29.1pp | -48.6%-2.9pp | -30.3% | -35.0%+7.7pp |
| Current Ratio | 0.26-0.6x | 0.53-1.4x | 1.19-2.0x | 1.86-1.3x | 0.91+0.6x | 1.93+1.7x | 3.17+2.4x | 3.19+1.4x |
| Liabilities-to-Equity | N/A | 18.54+17.9x | 1.53+1.2x | 0.64+0.3x | 1.81 | 0.67-23.7x | 0.38-0.2x | 0.380.0x |
| Asset Turnover | 0.25+0.1x | 0.13+0.1x | 0.080.0x | 0.050.0x | 0.15+0.1x | 0.010.0x | 0.06 | 0.010.0x |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| HARVARD APPRATS REG TCH HRGN | FY2025 | $704K | -$6.9M | N/A | $40.0M | — |
| ACCUSTEM SCIENCES INC ACUT | FY2025 | N/A | -$1.8M | N/A | $2.1M | — |
| PROVECTUS BIOPHARMS PVCT | FY2025 | $336K | N/A | N/A | $21.0M | — |
Where HARVARD APPRATS REG TCH Ranks
Frequently Asked Questions
What is HARVARD APPRATS REG TCH's annual revenue?
HARVARD APPRATS REG TCH (HRGN) reported $704K in total revenue for fiscal year 2025. This represents a 63.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is HARVARD APPRATS REG TCH's revenue growing?
HARVARD APPRATS REG TCH (HRGN) revenue grew by 63.7% year-over-year, from $430K to $704K in fiscal year 2025.
Is HARVARD APPRATS REG TCH profitable?
No, HARVARD APPRATS REG TCH (HRGN) reported a net loss of $6.7M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $6.9M.
What is HARVARD APPRATS REG TCH's EBITDA?
HARVARD APPRATS REG TCH (HRGN) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is HARVARD APPRATS REG TCH's gross margin?
HARVARD APPRATS REG TCH (HRGN) had a gross margin of 8.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is HARVARD APPRATS REG TCH's return on equity (ROE)?
HARVARD APPRATS REG TCH (HRGN) has a return on equity of -649.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is HARVARD APPRATS REG TCH's operating cash flow?
HARVARD APPRATS REG TCH (HRGN) recorded an outflow of $3.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are HARVARD APPRATS REG TCH's total assets?
HARVARD APPRATS REG TCH (HRGN) had $2.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does HARVARD APPRATS REG TCH spend on research and development?
HARVARD APPRATS REG TCH (HRGN) invested $2.7M in research and development during fiscal year 2025.
What is HARVARD APPRATS REG TCH's current ratio?
HARVARD APPRATS REG TCH (HRGN) had a current ratio of 1.19 as of fiscal year 2025, which is considered adequate.
What is HARVARD APPRATS REG TCH's liabilities-to-equity ratio?
HARVARD APPRATS REG TCH (HRGN) had a liabilities-to-equity ratio of 1.53 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is HARVARD APPRATS REG TCH's return on assets (ROA)?
HARVARD APPRATS REG TCH (HRGN) had a return on assets of -256.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is HARVARD APPRATS REG TCH's P/E ratio?
HARVARD APPRATS REG TCH (HRGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $40.0M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is HARVARD APPRATS REG TCH's price-to-sales ratio?
HARVARD APPRATS REG TCH (HRGN) trades at 40.7x sales, its market capitalization divided by $982K revenue, trailing 12 months to June 30, 2026. The market capitalization is $40.0M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does HARVARD APPRATS REG TCH's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, HARVARD APPRATS REG TCH (HRGN) held $1.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.8M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is HARVARD APPRATS REG TCH's Altman Z-Score?
HARVARD APPRATS REG TCH (HRGN) has an Altman Z-Score of -49.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is HARVARD APPRATS REG TCH's Piotroski F-Score?
HARVARD APPRATS REG TCH (HRGN) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are HARVARD APPRATS REG TCH's earnings high quality?
HARVARD APPRATS REG TCH (HRGN) reported a net loss of $6.9M while operations used $3.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can HARVARD APPRATS REG TCH cover its interest payments?
HARVARD APPRATS REG TCH (HRGN) reported an operating loss of $6.9M against $8K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.